AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BIOVENTIX PLC

Major Shareholding Notification May 18, 2015

7520_mrq_2015-05-18_92a7dbf7-dc66-477f-a7c7-151d21f8c4a3.html

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

BIOVENTIX PLC - Holdings in Company

PR Newswire

London, May 18

                             Bioventix plc                        ("Bioventix" or the "Company")                              Holdings in CompanyBioventix plc (AIM: BVXP) was notified on 18 May 2015 that Adrian Williams nowhas a total beneficial holding of 253,372\* ordinary shares of 5 pence each("Ordinary Shares") in the Company. This represents approximately 5.02% of theCompany's issued share capital.\*  Of the total holding, 237,534 are held in his own name, with the balance of   15,838 being held by DM plc, of which Mr Williams is the ultimate   controlling party.For further information please contact:Bioventix plc              Chief Executive Officer    Tel: 01252 728 001Peter HarrisonfinnCap Ltd                Corporate Finance          Tel: 020 7220 0500Geoff Nash/Simon Hicks     Corporate BrokingSteve NorcrossAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.

Talk to a Data Expert

Have a question? We'll get back to you promptly.